Jami Mandelin | BiotechTV

top of page

BIO-Europe 2026: Finland based Kasvu Therapeutics is trying to induce the benefits of psychedelics without the hallucination aspect by modulating TrkB receptors in the brain

Co-Founder & CEO Jami Mandelin describes the scientific rationale behind this approach, which they believe is a novel breakthrough. The company recently announced a €30M series A. Coverage brought to you by

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page

BIO-Europe 2026: Finland based Kasvu Therapeutics is trying to induce the benefits of psychedelics without the hallucination aspect by modulating TrkB receptors in the brain

Follow BiotechTV

Sponsors

Sponsor Spotlight